Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. (10th December 2014)

• Record Type: Journal Article
• Authors: Fleming, P.; Roubille, C.; Richer, V.; Starnino, T.; McCourt, C.; McFarlane, A.; Siu, S.; Kraft, J.; Lynde, C.; Pope, J.E.; Keeling, S.; Dutz, J.; Bessette, L.; Bissonnette, R.; Haraoui, B.; Gulliver, W.P.
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 29:Number 6(2015:Jun.)
• Page Start: 1063
• Page End: 1070
• Publication Date: 2014-12-10
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.12909
• Languages: English
• ISSNs: 0926-9959

Abstract

<abstract abstract-type="main" id="jdv12909-abs-0001"> <title>Abstract</title> <sec id="jdv12909-sec-0001" sec-type="section"> <title>Background</title> <p>Twenty to fifty percent of patients with psoriasis have depressive symptoms.</p> </sec> <sec id="jdv12909-sec-0002" sec-type="section"> <title>Objective</title> <p>To describe the effects of biologics (tumour necrosis factor inhibitors [TNFi] or interleukin 12/23 inhibitors [IL‐12/23i]) on depressive symptoms in patients with psoriasis.</p> </sec> <sec id="jdv12909-sec-0003" sec-type="section"> <title>Methods</title> <p>Electronic databases were searched for randomized controlled trials (RCTs) examining the effects of biologics on depressive symptoms in adults with psoriasis.</p> </sec> <sec id="jdv12909-sec-0004" sec-type="section"> <title>Results</title> <p>Of the 305 publications identified, three RCTs were included in a systematic review. In a trial evaluating ustekinumab, mean change in Hospital and Anxiety Depression Rating Scale at 24 weeks from baseline was 3.1 with ustekinumab (<italic>P </italic>< 0.001) vs. 0.21 with placebo (not significant). In a trial evaluating adalimumab, mean change in Zung Self‐Rating Depression Scale at 12 weeks from baseline was −6.7 with adalimumab vs. −1.5 with placebo. In a trial evaluating etanercept, the between‐group difference at 12 weeks in Beck Depression Inventory Scale was 1.8 (95% CI: 0.6, 2.90) in favour of etanercept over placebo. Limitations are that diagnostic criteria for depression were not used and scales and data from individual RCTs could not be combined.</p> </sec> <sec id="jdv12909-sec-0005" sec-type="section"> <title>Conclusion</title> <p>Adalimumab, etanercept and ustekinumab were associated with statistically significant reductions in depressive symptom scores using various scales in patients with moderate‐to‐severe psoriasis.</p> </sec> </abstract>